

Date : 30.05.2016

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai. - 400 001

The Manager (Listing Department)  
The Ahmedabad Stock Exchange Ltd.,  
Kamadhenu Complex,  
Opp. Sahajanand College, Panjarapole,  
Ahmedabad

**Sub: Outcome of the Board Meeting**

Please find enclosed Outcome of the board meeting held on 30<sup>th</sup> May, 2016

This is for your information and record.

Thanking you

for TRIMURTHI LIMITED,



**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

Date: 30-05-2016

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai. - 400 001

The Manager (Listing Department)  
The Ahmedabad Stock Exchange Ltd.,  
Kamadhenu Complex,  
Opp. Sahajanand College, Panjarapole,  
Ahmedabad

**Sub : Outcome of the Board meeting.**

The meeting of the Board of Directors of the company started at 4:30 pm today. The outcome of the meeting is under:

The Board has considered and approved the minutes of the previous board meeting.

The board has considered and approved the Audited Financial Results and Annual Accounts for the year ended 31<sup>st</sup> March, 2016.

In this regard , the following documents are attached :

1. Audited Standalone and consolidated Financial Results for the year ended 31<sup>st</sup> March ,2016 along with the report of Statutory Auditor .
2. Form A

The Chairman has updated the board about appointment of Women Director and the matter was deferred by the board.

The Board has Considered and Approved appointment of M/s Ramesh Athasniya & Co as Internal Auditor for the F.Y 2016-17.

The board has also Considered and approved Appointment of M/s. P.K Associates as the Secretarial Auditors for the year ending 31<sup>st</sup>, March 2016.

There being no other matter meeting of the board of directors concluded with the vote of thanks.

Thanking you  
for TRIMURTHI LIMITED,

  
Arun Kumar Bhangadia  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE AUDITED QUARTERLY RESULTS FOR THE QUARTER/YEAR ENDED MARCH, 2016.



**TRIMURTHI**  
(Rs. in Lakhs)

PART-I

**STATEMENT OF STANDALONE AUDITED RESULTS FOR QUARTER IV AND THREE MONTHS ENDED 31-03-2016**

Particulars	3 Months ended 31-03-2016	Preceeding 3 months ended 31-12-2015	Corresponding 3 months ended 31-03-2015	Year to date figures for the current period ended 31-03-2016	Year to date figures for the previous year ended 31-03-2015	Year ended 31-03-2015
	Audited	Unaudited	Audited	Audited	Audited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	0.00	0.00	0.00	0.00	31.40	31.40
Other Operating Income	27.21	24.08	30.76	93.00	114.23	114.23
<b>Total Operating Income (Net)</b>	<b>27.21</b>	<b>24.08</b>	<b>30.76</b>	<b>93.00</b>	<b>145.63</b>	<b>145.63</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil
b. Purchase of Traded Goods/Shares	0.00	0.00	0.00	0.00	0.08	0.08
c. (Increase)/Decrease in stock in trade and work in Progress	0.00	0.00	0.00	0.00	32.21	32.21
d. Employees Cost	8.37	5.76	2.37	23.94	6.22	6.22
e. Rent	0.55	0.60	0.36	1.65	1.20	1.20
f. Depreciation	8.06	10.97	17.03	33.60	39.57	39.57
g. Other Expenditure	14.25	3.18	22.30	27.78	36.54	36.54
<b>Total</b>	<b>31.22</b>	<b>20.51</b>	<b>42.06</b>	<b>86.96</b>	<b>115.82</b>	<b>115.82</b>
<b>3. Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-1)</b>	<b>(4.02)</b>	<b>3.57</b>	<b>(11.30)</b>	<b>6.03</b>	<b>29.80</b>	<b>29.80</b>
4. Other Income	(3.60)	2.76	(20.63)	7.52	(20.63)	(20.63)
<b>5. Profit/ (Loss) from Ordinary Activities before Finance Cost &amp; Exceptional Items (3+4)</b>	<b>(7.61)</b>	<b>6.33</b>	<b>(31.93)</b>	<b>13.56</b>	<b>9.17</b>	<b>9.17</b>
6. Finance Cost	0.00	0.00	0.13	0.00	0.39	0.39
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)</b>	<b>(7.61)</b>	<b>6.33</b>	<b>(32.06)</b>	<b>13.56</b>	<b>8.78</b>	<b>8.78</b>
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
<b>9. Profit/ (Loss) from Ordinary activities before tax (7+8)</b>	<b>(7.61)</b>	<b>6.33</b>	<b>(32.06)</b>	<b>13.56</b>	<b>8.78</b>	<b>8.78</b>
10. Tax Expense (Including Deferred Tax)	(1.61)	4.95	(6.08)	3.73	6.92	6.92
<b>11. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)</b>	<b>(6.01)</b>	<b>1.39</b>	<b>(25.98)</b>	<b>9.82</b>	<b>1.86</b>	<b>1.86</b>
12. Extraordinary Items (Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil	Nil
<b>13. Net Profit/ (Loss) for the period</b>	<b>(6.01)</b>	<b>1.39</b>	<b>(25.98)</b>	<b>9.82</b>	<b>1.86</b>	<b>1.86</b>
14. Share Of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
15. Minority Interest	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
<b>16. Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)</b>	<b>(6.01)</b>	<b>1.39</b>	<b>(25.98)</b>	<b>9.82</b>	<b>1.86</b>	<b>1.86</b>
17. Paid-up Equity Share Capital (Face Value of Rs 10/- each)	810.00	810.00	810.00	810.00	810.00	810.00
18. Reserves excluding revaluation reserves, as per balance sheet of previous accounting	334.09	324.27	324.27	334.09	324.27	324.27
<b>19. Earnings Per Share (EPS)</b>						
i. Basic & Diluted before extraordinary items (not annualised)	(0.07)	0.02	(0.32)	0.12	0.02	0.02
ii. Basic & Diluted after extraordinary items (not annualised)	(0.07)	0.02	(0.32)	0.12	0.02	0.02



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLCD18956



**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE AUDITED QUARTERLY RESULTS FOR THE QUARTER/YEAR ENDED MARCH, 2016.



**TRIMURTHI**  
GROUP

PART-II

SELECT INFORMATION FOR QUARTER IV AND YEAR ENDED 31-03-2016

Particulars	3 Months ended 31-03-2016	Preceding 3 months ended 31-12-2015	Corresponding 3 months ended 31-03-2015	Year to date figures for the current period ended 31-03-2016	Year to date figures for the previous period ended 31-03-2015	Year ended 31-03-2015
	Audited	Unaudited	Audited	Audited	Audited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2849600	2849600	2849600	2849600	2849600	2849600
- Percentage of shareholding	35.18%	35.18%	35.18%	35.18%	35.18%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5250400	5250400	5250400	5250400	5250400	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	64.82%	64.82%	64.82%	64.82%	64.82%

12 Months Ended ( 31/03/2016)						
<b>B. Investor Complaints</b>						
Pending at the beginning of the quarter				-NIL-		
Received during the quarter				-NIL-		
Disposed during the quarter				-NIL-		
Remaining unsolved during the quarter				-NIL-		

**Segment Reporting**

Particulars	Quarters ended			Period ended		Year ended
	31/03/2016 Audited	31/12/2015 Unaudited	31/03/2015 Audited	31/03/2016 Audited	31/03/2015 Audited	31/03/2015 Audited
<b>1. Segment Revenue</b>						
a. Pharma Business	0.00	0.00	0.00	0.00	31.40	31.40
b. Financial Services	93.00	24.08	30.76	93.00	114.23	114.23
c. Investments	7.52	2.76	0.00	7.52	(19.67)	(19.67)
d. Trading in Shares	0.00	0.00	(19.67)	0.00	0.00	0.00
<b>Total</b>	<b>100.52</b>	<b>26.84</b>	<b>11.09</b>	<b>100.52</b>	<b>125.95</b>	<b>125.95</b>
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>100.52</b>	<b>26.84</b>	<b>11.09</b>	<b>100.52</b>	<b>125.95</b>	<b>125.95</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	0.00	0.00	(0.00)	0.00	(1.47)	(1.47)
b. Financial Services	6.32	3.06	(11.50)	6.32	30.81	30.81
c. Investments	7.24	3.26	(20.56)	7.24	(20.56)	(20.56)
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>13.56</b>	<b>6.32</b>	<b>(32.06)</b>	<b>13.56</b>	<b>8.78</b>	<b>8.78</b>
Less:						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>13.56</b>	<b>6.32</b>	<b>(32.06)</b>	<b>13.56</b>	<b>8.78</b>	<b>8.78</b>
<b>3. Capital Employed</b>						
a. Pharma Business	0.00	9.18	11.93	-Nil-	11.83	11.83
b. Financial Services	842.40	962.94	962.16	842.40	962.16	962.16
c. Investments	301.69	172.96	140.28	301.69	140.28	140.28
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>1144.09</b>	<b>1145.10</b>	<b>1114.27</b>	<b>1144.09</b>	<b>1114.27</b>	<b>1114.27</b>

**Notes:**

- The above results have been taken on record by the board of directors of the company at their meeting held on 30-05-2016.
- The financial results for the quarter ended 31-03-2016 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

Place : Hyderabad-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





# TRIMURTHI LIMITED

(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED ON 31-03-2016



TRIMURTHI  
GROUP

(Rupees in Lacs)

Particulars	As at 31/03/2016	As at 31/03/2015
<b>A. EQUITY AND LIABILITIES</b>		
<b>1. Share Holders' Funds:</b>		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	334.09	324.27
(c) Money received against warrants	0.00	0.00
<b>Sub-Total Share Holders' Funds</b>	<b>1144.09</b>	<b>1134.27</b>
<b>2. Share Application pending for Allotment</b>	-Nil-	-Nil-
<b>3. Minority Interest*</b>	-Nil-	-Nil-
<b>4. Non Current Liabilities:</b>		
(a) Long Term Borrowings	-Nil-	-Nil-
(b) Deferred Tax Liabilities (Net)	2.35	8.27
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
<b>Sub-Total Non Current Liabilities</b>	<b>2.35</b>	<b>8.27</b>
<b>4. Current Liabilities</b>		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	-Nil-	-Nil-
(c) Other Current Liabilities	7.55	7.48
(d) Short Term Provisions	9.66	10.24
(e) Inter Division	-Nil-	-Nil-
<b>Sub-Total Current Liabilities</b>	<b>17.21</b>	<b>17.72</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>1163.64</b>	<b>1160.26</b>
<b>B. ASSETS</b>		
<b>1. Non-Current Assets:</b>		
(a) Fixed Assets	63.61	74.94
(b) Non-Current Investments	136.80	140.28
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.90	20.52
(e) Other Non-Current Assets	2.24	-Nil-
<b>Sub-Total Non Current Assets</b>	<b>223.55</b>	<b>235.74</b>
<b>2. Current Assets:</b>		
(a) Current Investments	164.16	-Nil-
(b) Inventories	-Nil-	-Nil-
(c) Trade Receivables	0.73	11.83
(d) Cash & Cash Equivalents	44.42	17.48
(e) Short Term Loans and Advances	719.57	881.46
(f) Other Current Liabilities	11.21	13.75
<b>Sub-Total Current Assets</b>	<b>940.10</b>	<b>924.52</b>
<b>TOTAL ASSETS</b>	<b>1163.64</b>	<b>1160.26</b>

**TOTAL ASSETS**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





# TRIMURTHI LIMITED

(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
CONSOLIDATED AUDITED QUARTERLY RESULTS FOR THE QUARTER/YEAR ENDED MARCH, 2016



TRIMURTHI (Rs. in Lakhs)

PART-I STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR QUARTER IV AND THREE MONTHS ENDED 31/03/2016						
Particulars	3 Months ended 31-03-2016	Preceding 3 months ended 31-12-2015	Corresponding 3 months ended 31-03-2015	Year to date figures for the current period ended 31-03-2016	Year to date figures for the previous period ended 31-03-2015	Year ended 31-03-2015
	Audited	Unaudited	Audited	Audited	Audited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	99.21	125.75	100.34	470.83	511.51	511.51
Other Operating Income	31.48	22.88	39.98	100.76	123.45	123.45
<b>Total Operating Income(Net)</b>	<b>130.69</b>	<b>148.63</b>	<b>140.32</b>	<b>571.59</b>	<b>634.96</b>	<b>634.96</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil
b. Purchase of Traded Goods	84.66	102.56	95.64	411.89	472.24	472.24
c. (Increase)/Decrease in stock in trade and work in Progress	3.86	4.67	4.32	(0.64)	(12.80)	(12.80)
d. Employees Cost	22.82	13.44	17.18	60.43	35.86	35.86
e. Depreciation	8.78	10.51	17.37	35.08	40.89	40.89
f. Other Expenditure	19.33	5.95	26.78	44.67	50.63	50.63
<b>Total</b>	<b>139.45</b>	<b>137.13</b>	<b>161.28</b>	<b>551.43</b>	<b>586.82</b>	<b>586.82</b>
<b>3. Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-1)</b>	<b>(8.76)</b>	<b>11.49</b>	<b>(20.96)</b>	<b>20.16</b>	<b>48.14</b>	<b>48.14</b>
4. Other Income	1.98	2.79	(20.63)	13.23	(20.63)	(20.63)
<b>5. Profit/ (Loss) from Ordinary Activities before Finance Cost &amp; Exceptional Items (3+4)</b>	<b>(6.78)</b>	<b>14.28</b>	<b>(41.59)</b>	<b>33.39</b>	<b>27.51</b>	<b>27.51</b>
6. Finance Cost	0.06	0.00	0.13	0.06	0.39	0.39
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)</b>	<b>(6.84)</b>	<b>14.28</b>	<b>(41.72)</b>	<b>33.33</b>	<b>27.12</b>	<b>27.12</b>
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
<b>9. Profit/ (Loss) from Ordinary activities before Prior period items and tax (7+8)</b>	<b>(6.84)</b>	<b>14.28</b>	<b>(41.72)</b>	<b>33.33</b>	<b>27.12</b>	<b>27.12</b>
10. Prior period Items	9.17	Nil	Nil	9.17	Nil	Nil
<b>11. Profit/ (Loss) from Ordinary activities before tax (7+8)</b>	<b>(16.01)</b>	<b>14.28</b>	<b>(41.72)</b>	<b>24.16</b>	<b>27.12</b>	<b>27.12</b>
11. Tax Expense (Including Deferred Tax)	0.76	2.52	(8.73)	11.20	12.94	12.94
<b>12. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)</b>	<b>(16.77)</b>	<b>11.76</b>	<b>(33.00)</b>	<b>12.96</b>	<b>14.18</b>	<b>14.18</b>
13. Extraordinary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil	Nil
<b>14. Net Profit/ (Loss) for the period (11+12)</b>	<b>(16.77)</b>	<b>11.76</b>	<b>(33.00)</b>	<b>12.96</b>	<b>14.18</b>	<b>14.18</b>
15. Share Of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
16. Minority Interest	(1.92)	1.52	(2.26)	3.04	5.67	5.67
<b>17. Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)</b>	<b>(14.86)</b>	<b>10.24</b>	<b>(30.74)</b>	<b>9.91</b>	<b>8.51</b>	<b>8.51</b>
18. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00	810.00
19. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	345.11	332.90	336.82	345.11	336.82	336.82
<b>20. Earnings Per Share (EPS)</b>						
i. Basic & Diluted before extraordinary items (not annualised)	(0.18)	0.13	(0.38)	0.12	0.11	0.11
ii. Basic & Diluted after extraordinary items (not annualised)	(0.18)	0.13	(0.38)	0.12	0.11	0.11



## TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA, | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
CONSOLIDATED AUDITED QUARTERLY RESULTS FOR THE QUARTER/YEAR ENDED MARCH, 2016



**TRIMURTHI**  
GROUP

**PART-II**

Select Information for Quarter IV and Three months Ended 31/03/2016

Particulars	3 Months ended 31-03-2016	Preceding 3 months ended 31-12-2015	Corresponding 3 months ended 31-03-2015	Year to date figures for the current period ended 31-03-2016	Year to date figures for the previous period ended 31-03-2015	Year ended 31-03-2015
	Audited	Unaudited	Audited	Audited	Audited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2849600	2849600	2849600	2849600	2849600	2849600
- Percentage of shareholding	35.18%	35.18%	35.18%	35.18%	35.18%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5250400	5250400	5250400	5250400	5250400	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	64.82%	64.82%	64.82%	64.82%	64.82%
<b>12 Months Ended ( 31/03/2016)</b>						
<b>B. Investor Complaints</b>						
Pending at the beginning of the quarter				-NIL-		
Received during the quarter				-NIL-		
Disposed during the quarter				-NIL-		
Remaining unsolved during the quarter				-NIL-		

**Segment Reporting**

Particulars	Quarters ended			Period ended		Year ended
	31/03/2016	31/12/2015	31/03/2015	31/03/2016	31/03/2015	31/03/2015
	Audited	Unaudited	Audited	Audited	Audited	Audited
<b>1. Segment Revenue</b>						
a. Pharma Business	106.98	121.62	109.51	478.60	520.68	520.68
b. Financial Services	23.72	27.00	30.81	83.00	114.28	114.28
c. Investments	1.98	2.79	(19.67)	13.23	(19.67)	(19.67)
d. Foods	0.00	0.00	0.00	0.00	0.00	0.00
e. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>132.67</b>	<b>151.41</b>	<b>120.65</b>	<b>584.82</b>	<b>615.29</b>	<b>615.29</b>
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>132.67</b>	<b>151.41</b>	<b>120.65</b>	<b>584.82</b>	<b>615.29</b>	<b>615.29</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	2.77	3.17	(10.70)	19.26	16.82	16.82
b. Financial Services	(10.60)	7.82	(10.32)	2.41	31.00	31.00
c. Investments	2.26	3.29	(20.70)	12.94	(20.70)	(20.70)
d. Foods	0.00	0.00	0.00	0.00	0.00	0.00
e. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>(5.57)</b>	<b>14.28</b>	<b>(41.72)</b>	<b>34.60</b>	<b>27.12</b>	<b>27.12</b>
Less:						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>(5.57)</b>	<b>14.28</b>	<b>(41.72)</b>	<b>34.60</b>	<b>27.12</b>	<b>27.12</b>
<b>3. Capital Employed</b>						
a. Pharma Business	61.18	57.05	68.68	61.18	68.68	68.68
b. Financial Services	910.43	977.66	940.43	910.43	940.43	940.43
c. Investments	169.89	108.24	113.79	169.89	113.79	113.79
d. Foods	64.33	64.33	0.00	64.33	0.00	0.00
e. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>1205.83</b>	<b>1207.28</b>	<b>1122.90</b>	<b>1205.83</b>	<b>1122.90</b>	<b>1122.90</b>

**Notes:**

- The above results have been taken on record by the board of directors of the company at their meeting held on 30-05-2016.
- The financial results for the quarter ended 31-03-2016 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting, certain costs that are used interchangeably not allocated to the individual segment above.
- The above results includes the results of Trimurthi Foods Limited which has become the subsidiary of the Company from Quarter (Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

Place : Hyderabad - 231/1/2/ABC, Indrabagh, Sultanbazar.  
Date : 30-05-2016  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







**TRIMURTHI LIMITED**  
**CONSOLIDATED ASSETS AND LIABILITIES FOR THE YEAR ENDED ON 31-03-2016**

**TRIMURTHI GROUP**  
(Rupees in Lacs)

Particulars	As at 31/03/2016	As at 31/03/2015
<b>A. EQUITY AND LIABILITIES</b>		
<b>1. Share Holders' Funds:</b>		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	345.11	332.90
(c) Money received against warrants		
<b>Sub-Total Share Holders' Funds</b>	<b>1155.11</b>	<b>1142.90</b>
<b>2. Share Application pending for Allotment</b>	-Nil-	-Nil-
<b>3. Minority Interest*</b>	50.72	27.54
<b>4. Non Current Liabilities:</b>		
(a) Long Term Borrowings	-Nil-	-Nil-
(b) Deferred Tax Liabilities (Net)	2.38	8.32
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
<b>Sub-Total Non Current Liabilities</b>	<b>2.38</b>	<b>8.32</b>
<b>5. Current Liabilities</b>		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	36.98	48.07
(c) Other Current Liabilities	11.18	8.48
(d) Short Term Provisions	17.14	16.22
(e) Inter Division	-Nil-	-Nil-
<b>Sub-Total Current Liabilities</b>	<b>65.29</b>	<b>72.77</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>1273.51</b>	<b>1251.53</b>
<b>B. ASSETS</b>		
<b>1. Non-Current Assets:</b>		
(a) Fixed Assets	96.11	75.28
(b) Non-Current Investments	5.00	113.78
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.90	20.51
(e) Other Non-Current Assets	7.61	-Nil-
<b>Sub-Total Non Current Assets</b>	<b>129.62</b>	<b>209.57</b>
<b>2. Current Assets:</b>		
(a) Current Investments	164.16	-Nil-
(b) Inventories	45.65	45.01
(c) Trade Receivables	53.24	71.75
(d) Cash & Cash Equivalents	143.39	21.80
(e) Short Term Loans and Advances	721.69	881.24
(f) Other Current Assets	15.76	22.16
<b>Sub-Total Current Assets</b>	<b>1143.89</b>	<b>1041.96</b>
<b>TOTAL ASSETS</b>	<b>1273.51</b>	<b>1251.53</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
 4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
 Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
 Email : info@trimurthidrugs.com  
 Website : www.trimurthidrugs.com  
 CIN No. : L67120TG1994PLC018956







# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### Independent Auditor's Report

To the Members of

M/S TRIMURTHI LIMITED ( formerly known as 'TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED' )

### Report on the Standalone Financial Statements.

1. I have audited the accompanying financial statements of TRIMURTHI LIMITED ( formerly known as 'TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED' ) ('the Company'), which comprise the balance sheet as at 31<sup>st</sup> March 2016, the statement of profit and loss and cash flow statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

### Management's Responsibility for the Standalone Financial Statements

2. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

3. My responsibility is to express an opinion on these financial statements based on my audit. I have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

4. I conducted my audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

5. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment,



# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

6. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion on the financial statements.

### Opinion:

7. In my opinion and to the best of my information and according to the explanations given to me, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India.

- a) In the case of the Balance sheet, of the state of affairs of the company as at 31<sup>st</sup> March, 2016.
- b) In the case of the statement of profit and loss, of the Profit for the year ended on that date and
- c) In the case of the cash flow statement, of the cash flows of the company for the year ended on that date.

### Report on Other Legal and Regulatory Requirements

8. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters specified in the paragraph 3 and 4 of the Order, to the extent applicable.

9. As required by Section 143 (3) of the Act, we report that:

(a) I have sought and obtained all the information and explanations which to the best of my knowledge and belief were necessary for the purposes of our audit.

(b) In my opinion proper books of account as required by law have been kept by the Company so far as it appears from my examination of those books;

(c) The balance sheet, the statement of profit and loss and the cash flow statement dealt with by this Report are in agreement with the books of account;

(d) In my opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;





# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

(e) on the basis of the written representations received from the directors as on 31 March 2016 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2016 from being appointed as a director in terms of Section 164 (2) of the Act; and

(f) with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in my opinion and to the best of my information and according to the explanations given to me.

i. The Company has disclosed the impact of pending litigation on its financial position in its financial statements.

ii. As the company is not having any long term contracts including derivatives contracts the provision on foreseeable losses is not applicable.

iii. The company is not required to transfer any funds to Investor Education and protection fund.

FOR K.VENKATESWARA RAO & ASSOCIATES  
CHARTERED ACCOUNTANTS

FRN: 006374S  
K.VENKATESWARA RAO  
PROPRIETOR  
M.NO.27305

A circular stamp with a double border. The outer border contains the text 'K. Venkateswara Rao & Associates' at the top and 'Chartered Accountants' at the bottom. In the center, there is a handwritten signature in blue ink. Below the signature, the text 'K.VENKATESWARA RAO' and 'PROPRIETOR' is printed. At the very bottom of the stamp, 'M.NO.27305' is printed.

PLACE: HYDERABAD  
Date: 30.05.2016



# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### ANNEXURE TO THE AUDITOR'S REPORT

The Annexure referred to in paragraph 8 in our Independent Auditors' Report to the members of the Company on the financial statements for the year ended 31 March 2016, we report that:

- (i) (a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.  
  
(b) All the fixed assets have been physically verified by the management during the year. In accordance with the program, certain fixed assets were verified during the year and no material discrepancies were noticed on such verification. In my opinion, the physical verification is reasonable having regard to the size of the Company and the nature of its assets.  
  
(c) According to the information and explanations given to me and on the basis of my examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
- (ii) The company is not having any inventory during the year and hence this clause is not applicable.
- (iii) In my opinion and according to the information and explanations given to me, the company has not granted any loans secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013.
- (iv) In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made.
- (v) In my opinion and according to the information and explanations given to me, the company has not accepted any deposits from the public during the year under reference.
- (vi) The central government has not prescribed maintenance of cost records under section 148(1) of the Companies Act 2013.





# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayalnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

- (vii) (a) The company is regular in depositing with appropriate authorities undisputed statutory dues including Income Tax, Service Tax.
- (b) According to the information and explanations given to me, there are no dues of income tax, sales tax, Value added tax, Service Tax and Cess, which have not been deposited on account of any dispute.
- (viii) The Company does not have any loans or borrowings from any financial institution, banks, government or debenture holders during the year. Accordingly, paragraph 3(viii) of the Order is not applicable.
- (ix) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, paragraph 3 (ix) of the Order is not applicable.
- (x) According to the information and explanations given to me, no fraud on or by the company has been noticed or reported during the courses of my audit.
- (xi) According to the information and explanations give to me and based on my examination of the records of the Company, the Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
- (xii) In my opinion and according to the information and explanations given to me, the Company is not a nidhi company. Accordingly, paragraph 3(xii) of the Order is not applicable.
- (xiii) According to the information and explanations given to me and based on my examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) According to the information and explanations give to me and based on my examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
- (xv) According to the information and explanations given to me and based on my examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Order is not applicable.



# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934.

PLACE: HYDERABAD  
DATE: 30-05-2016

For K.VENKATESWARA RAO & ASSOCIATES

CHARTERED ACCOUNTANTS

FRN Q063745

(K.VENKATESWARA RAO)

(PROPRIETOR)

M.NO.027305







# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### Independent Auditors' Report on Consolidated Financial Statements

To The Board of Directors of Trimurthi Limited ( Formerly known as Trimurthi Drugs & Pharmaceuticals limited ).

#### Report on Consolidated Financial Statements

I have audited the accompanying consolidated financial statements of Trimurthi Limited ( Formerly known as Trimurthi Drugs & Pharmaceuticals Limited ) ('the Holding Company') and its subsidiaries, which comprise the consolidated balance sheet as at 31 March 2016, the consolidated statement of profit and loss and consolidated cash flows statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

#### Management's Responsibility for the Consolidated Financial Statements:

Management is responsible for the preparation and presentation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Company in accordance with accounting principles generally accepted in India. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

#### Auditor's Responsibility:

My responsibility is to express an opinion on these consolidated financial statements based on my audit. I conducted audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and presentation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls systems over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.



# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lpk, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### Opinion:

In my opinion and to the best of my information and according to the explanations given to me, the consolidated financial statements give a true and fair view in conformity with the accounting principles generally accepted in India:

(i) In the case of the consolidated balance sheet, of the state of affairs of the Company as at 31 March 2016;

(ii) In the case of the consolidated statement of profit and loss, of the profit for the year ended on that date; and

(iii) In the case of the consolidated cash flow statement, of the cash flows for the year ended on that date.

### Report on Other Legal and Regulatory Requirements:

As required by Section 143(3) of the Act, we report, to the extent applicable, that:

- a. I have sought and obtained all the information and explanations which to the best of my knowledge and belief were necessary for the purposes of audit of the aforesaid consolidated financial statements.
- b. In my opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from examination of those books.
- c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
- d. In my opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2016 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies incorporated in India, none of the directors of the Group companies incorporated in India is disqualified as on 31st March, 2016 from being appointed as a director in terms of Section 164 (2) of the Act.





# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

- f. With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure A"; and
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in my opinion and to the best of my information and according to the explanations given to us:
  - i. The consolidated financial statements are not having any pending litigations.
  - ii. The Consolidated financial statements are not having any long term contracts including derivatives contracts the provision on foreseeable losses is not applicable.
  - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the company.

For K.VENKATESWARA RAO & ASSOCIATES  
CHARTERED ACCOUNTANTS  
ERN 106374  
  
[K.VENKATESWARA RAO]  
(PROPRIETOR)  
M.NO.027305

PLACE: HYDERABAD  
DATE: 30.05.2016.



# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### Annexure -A to the Auditors' Report

#### Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended 31 March 2016, we have audited the internal financial controls over financial reporting of Trimurthi Limited ( Formerly known as Trimurthi Drugs & Pharmaceuticals Limited ) ("the Holding Company") and its subsidiary companies which are companies incorporated in India, as of that date.

#### Management's Responsibility for Internal Financial Controls:

The Respective Board of Directors of the Holding Company and its subsidiary companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### Auditors' Responsibility

My responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by ICAI and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

I believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for my audit opinion on the Company's internal financial controls system over financial reporting.





# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### Opinion

In my opinion, the Holding Company and its subsidiary companies, which are companies incorporated in India, have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2016, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For K.VENKATESWARA RAO & ASSOCIATES  
CHARTERED ACCOUNTANTS  
FRN 0063745

(K.VENKATESWARA RAO)  
(PROPRIETOR)  
M.NO.027305

PLACE: HYDERABAD  
DATE: 30.05.2016.

**Compliance under Regulation 33 of Securities and Exchange Board Of India (Listing Obligations and Disclosure Requirements) Requirements, 2015**

**FORM A  
Annual Audit Report**

1.	Name of the company	TRIMURTHI LIMITED(Formerly Known As Trimurthi Drugs & Pharmaceuticals Ltd.,)
2.	Annual financial statements for year ended	31 <sup>st</sup> March, 2016 (Board Meeting - Monday, 30/05/2016)
3.	Type of Audit observation	Un - Qualified
4.	Frequency of observation	Not Applicable
	<b>Managing Director</b>	Mr. Arun Kumar Bhangadia, (DIN: 00021024)  
	<b>Chief Financial Officer (CFO)</b>	Ms. Manda Vani (PAN No. ALFPM74110)  
	<b>Statutory Auditor of the Company</b>	Mr. K. Venkateshwara Rao, Proprietor (K. Venkateshwara Rao & Associates., Chartered Accountants) Firm Reg. No. 0063745 / Membership No. 027305  
	<b>Chairman of Audit Committee</b>	Mr. Ram Swaroop Agrawal(DIN:00021232)  